期刊
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
卷 110, 期 41, 页码 16538-16543出版社
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1315295110
关键词
CD4bs; glycan; gp160
资金
- Stavros Niarchos Foundation
- Starr Foundation
- Agence Nationale de Recherche sur le Sida
- Sidaction
- AREVA Foundation
- Vaccine Research Institute
- Labex Integrative Biology of Emerging Infectious Diseases program
- Seventh Framework Programme HIT Hidden HIV [Health-F3-2012-305762]
- Institut Pasteur
- Bill and Melinda Gates Foundation
- Collaboration for AIDS Vaccine Discovery Grants [38660, 38619s]
- German Center for Infection Research [UL1 TR000043, AI 100663-01]
- Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery
- Comprehensive Antibody Vaccine Immune Monitoring Consortium Grant [1032144]
- [AI 100148-01]
Effective control of HIV-1 infection in humans is achieved using combinations of antiretroviral therapy (ART) drugs. In humanized mice (hu-mice), control of viremia can be achieved using either ART or by immunotherapy using combinations of broadly neutralizing antibodies (bNAbs). Here we show that treatment of HIV-1-infected hu-mice with a combination of three highly potent bNAbs not only resulted in complete viremic control but also led to a reduction in cell-associated HIV-1 DNA. Moreover, lowering the initial viral load by coadministration of ART and immunotherapy enabled prolonged viremic control by a single bNAb after ART was withdrawn. Similarly, a single injection of adeno-associated virus directing expression of one bNAb produced durable viremic control after ART was terminated. We conclude that immunotherapy reduces plasma viral load and cell-associated HIV-1 DNA and that decreasing the initial viral load enables single bNAbs to control viremia in hu-mice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据